Key Trends and Insights into the Xerostomia Therapeutics Market: Growth Rate and Opportunities to 2034
Get 15% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the xerostomia therapeutics market grown in recent years?
In the recent past, the xerostomia therapeutics market size has been making robust advancements. The market is projected to augment from $2.14 billion in 2024 to around $2.26 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.7%. This substantial growth during the historical period is chiefly due to increasing occurrences of xerostomia in the elderly population, advancements in research and development of efficient xerostomia products, enhanced awareness concerning xerostomia-associated products, a rise in medical conditions, and an increasing prevalence of chronic ailments.
How is the xerostomia therapeutics market size expected to evolve during the forecast period?
The market size of xerostomia therapeutics is projected to witness robust growth in the forthcoming years. The market is set to expand to $2.79 billion by 2029, with a compound annual growth rate (CAGR) of 5.3%. The market expansion in the forecast period can be ascribed to the easy procurement of reasonably priced medications, the growing incidence of oral health problems, enhanced consciousness amongst healthcare professionals, government schemes, and an uptick in the use of medication. Key trends during this forecast period incorporate the rise of artificial saliva and substitutes for saliva, advancements in technology and product innovation, personalised treatment and targeted care, telehealth combined with remote surveillance, and the emergence of non-invasive treatments.
Get your xerostomia therapeutics market report here!
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report
Which key drivers are propelling the xerostomia therapeutics market’s growth?
The xerostomia therapeutics market is expected to experience growth due to the rising use of chemotherapy in cancer treatments. Powerful medications used in chemotherapy can slow or even kill cancer cells, which is why its implementation is becoming widely accepted. This is largely attributed to its ability to specifically target and eliminate cancer cells in the entire body. Xerostomia therapeutics consist of medicines that stimulate saliva production or mouth rinses that enhance taste sensation, which makes it easier for patients to consume food and sustain adequate nutrition. In January 2022, the National Cancer Institute estimated that there are 18.1 million cancer survivors in the United States, comprising 5.4% of the total population. It is projected that by 2032, the global population of cancer survivors will reach 22.5 million — a 24.4% increase from current estimates. As such, the growing adoption of chemotherapy in cancer treatments is bolstering the expansion of the xerostomia therapeutics market.
What are the market segments in the xerostomia therapeutics industry?
The xerostomia therapeutics market covered in this report is segmented –
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric
Subsegments:
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp
What are the top market players propelling the growth of the xerostomia therapeutics industry?
Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc
What key trends are currently impacting the xerostomia therapeutics market’s development?
Major players in the xerostomia therapeutics market are innovating patient-centric, non-intrusive methods like oral spray to cater to the growing need for convenient and effective treatments for dry mouth. Oral sprays deliver targeted treatment to specific areas in the mouth, supplying necessary moisture and lubrication exactly where it’s required. For instance, Aquoral, a clinically tested oral spray designed to alleviate dry mouth or xerostomia, was introduced by K Pharmaceuticals, a pharmaceutical company based in India, in July 2023. This condition, which could result from different factors such as medications and diseases, can cause discomfort, make it difficult to chew and swallow, and lead to oral health issues. Aquoral provides continuous relief for up to six hours by creating a persistent protective layer over the oral cavity, which minimizes moisture loss and boosts comfort. In contrast to conventional aqueous-based therapies that need regular reapplication, Aquoral leverages patented Oxidized Glycerol Triesters (OGT), a lipid-based technology derived from plants that offers superior protection.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15700
Which regions are most influential in expanding the xerostomia therapeutics market?
North America was the largest region in the xerostomia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Post-Traumatic Stress Disorder Therapeutics Global Market Report 2024
Hepatitis Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Peptide Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
